QBIO News and Press, Q BioMed Inc From 11/14/22

Q BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC. PR Newswire Company converts future royalty into 15% equity in multi-billion dollar potential product portfolio with additional $20M royalty NEW YORK ...

Q BIOMED PROVIDES SHAREHOLDER UPDATE PR Newswire Focus on Portfolio Monetization and Roll-up Strategy NEW YORK , Oct. 11, 2022 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development comp...

Q BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKER PR Newswire Groundbreaking GDF15 biomarker may be the first single examination to accurately predict disease progression in Glaucoma The Certificate of Grant and European Patent No. ...

NEW YORK, NY / ACCESSWIRE / August 25, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Q BioMed. Mark had the pleasure of recently conducting the I...

Q BioMed Inc. Provides Update to Shareholders PR Newswire Company Reports Revenue Improvement and Positive Data on Pipeline Assets NEW YORK , July 29, 2022 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commerci...

Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer PR Newswire Publication in Pharmaceuticals in May 2022 is titled Augmented Eff...

Q BioMed Outlines Strategy and Value Proposition in Multi-Billion Dollar Markets PR Newswire Management's assessment and value of Q BioMed outlined NEW YORK , May 6, 2022 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) a commercial-stage biotechnol...

Q BioMed announces publication of research showing augmented efficacy of its drug candidate Uttroside-B against liver cancer Publication in Frontiers of Oncology dated February 8, 2022 is titled Blockade of Uttroside-B Induced Autophagic Pro-Survival Signals Augments Its Chemoth...

Q BioMed (OTCQB:QBIO) said it received $500K order for its Strontium Chloride USP Injections under a supply contract between its Canadian distribution partner isoSolutions Marketing and Management, and Chinese company Chengdu Syncor Pharmaceutical. The company said Strontium89 is an...

Q BioMed Announces Initial $500k Order of Strontium89 to Chinese Market Order Represents a small fraction of the overall market PR Newswire NEW YORK , March 7, 2022 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced...